报告题目：阻断肿瘤信号传导通路的抑制性抗体靶向药物

报告人：何苗壮，美国国家卫生研究院（NIH）教授，天美娱乐紫江讲座教授

主持人：钱旻 教授

报告时间：2017年3月22日 13:30-15:00

报告地点：闵行生科院534报告厅

主办单位：天美娱乐🙍🏿，科技处

 

报告人简介😯：Dr. Mitchell Ho is a Senior Investigator and Chief of the Antibody Therapy Section at the National Cancer Institute (NCI), NIH. He is also the Chair of the Department of Biochemistry for the FAES Graduate School at the NIH. He received a B.S. in Biology from East China Normal University and a M.A. in Cell and Molecular Biology from San Francisco State University. He became interested in phage display antibody engineering during his work at Protein Design Labs. He obtained a Ph.D. in Immunology from the University of Illinois at Urbana-Champaign where he received a NIDA/NRSA fellowship with Mariangela Segre to design anti-idiotypic antibodies as cocaine antagonists. He was a postdoctoral fellow with Ira Pastan at the NCI where Dr. Ho was involved in the development of recombinant immunotoxins targeting CD22 and mesothelin that are currently being tested in clinical trials including Phase III for cancer treatment. Dr. Ho serves on the Board of Distinguished Advisors for the Antibody Society.

 

报告摘要：Antibodies have a major role in cancer treatment. To increase their efficacy, Dr. Ho’s laboratory designs them to inhibit signaling pathways responsible for the growth of cancer. He has two main research areas. One focuses on decreasing the size of the antibody to make a 'single domain antibody' so it can target buried functional regions in receptors or signaling complexes. The second area is to identify new therapeutic targets with a focus on tumor-specific glypicans and make antibodies that modulate their activity. His group was the first to discover inhibitory antibodies with the unique ability to block Wnt/Yap signaling pathway via recognizing cryptic functional regions on glypican-3 in liver cancer. Several antibody therapeutics, including immunotoxins and chimeric antigen receptor T cells, are being developed in Dr. Ho’s laboratory for clinical applications.